Eventide Asset Management AAVXF Position
Active9-Fund ConvergenceEventide Asset Management trimmed their position in Abivax S.A. (AAVXF) in Q4 2025, holding $44.2M worth of shares across 327,911 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
AAVXF is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for ABX464 in 14 days (Apr 30, 2026), making the timing of Eventide's position particularly relevant.
About Abivax S.A.
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Full company profile →Eventide Asset Management AAVXF Position History
Frequently Asked Questions
Does Eventide Asset Management own AAVXF?
Yes. As of Q4 2025, Eventide Asset Management holds 327,911 shares of Abivax S.A. (AAVXF) valued at $44.2M. This data comes from their SEC 13F filing.
How many hedge funds own AAVXF?
9 specialist biotech hedge funds currently hold AAVXF, including Cormorant Asset Management, Baker Bros. Advisors, BVF Partners and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy AAVXF?
Eventide Asset Management's position in AAVXF was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's AAVXF position increasing or decreasing?
Eventide Asset Management trimmed their AAVXF position in the most recent quarter, reducing by 68,993 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AAVXFCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →